About Dr Jesse Kumar

Dr Jesse Kumar is a Specialist Consultant in Endocrinology, Diabetes and General Medicine.

Dr Kumar was appointed as a Consultant Endocrinologist in 2006. He had his higher specialist training in South Thames Deanery (Guy’s & St Thomas’ Hospital – London, Kent & Sussex) and held significant posts as Lead Physician, Clinical Director and Lead for Diabetes Commissioning since his appointment at Maidstone and Tunbridge Wells NHS Trust in 2006.

Dr Kumar has a special interest in Thyroid, Adrenal, calcium, hypogonadism, weight management and general endocrinology. He is ARSAC certified to prescribe radio-active iodine for hyperthyroidism and goitre.

Dr Kumar has an established interest in research and has been the Principle Investigator (PI) and Sub-Investigator (SI) in world-wide multicentre trials since 2006, including phase 3 (pre-market) & 4 (post-release) trials. He has numerous publications/presentations in international & national journals and conferences and supervises doctors for medical education.

Dr Kumar speaks five languages, maintains a keen interest in fitness and is a firm believer in an interface of modern technology with humanities as an adjunct to deliver effective outcomes in his clinical consultations.

Registrations & Memberships:
General Medical Council
ARSAC – Administration of Radioactive Substances Advisory Committee
Royal College of Physicians of London (Fellow)
European Thyroid Association
Society of Endocrinology
Medical Protection Society
British Medical Association
ABCD – association of British Clinical Diabetologists
HCSA – Hospital Consultant & Specialists Association
Member of Thyroid Cancer Core MDT

Qualifications:
MBBS, FRCP (Royal College of Physicians of London).
ARSAC certificate – Administration of Radioactive Substances Advisory Committee

Combination Thyroxine + T3 treatment in hypothyroidism – ETA guidelines 2012 help prescribing in hypothyroidism

Combination treatment with thyroxine and T3 has always remained controversial and uncommon (particularly the armour treatment) and the reluctance of endocrinologists to prescribe (which is very understandable). The controversy i.e. the paucity of evidence in medical  literature to support T4+T3 treatment – Vs – persistence of symptoms on adequate treatment with thyroxine (despite normal TSH) and reported improvement […]

Another weight reducing diabetes treatment approved by European Authority – Dapagliflozin

FORXIGA™ (dapagliflozin) has recently (mid-Nov 2012) been approved in European Union for treatment of type 2 diabetes – A wonderful ‘concept to reality’ story which originates from the ‘cider’ qualities of increasing loss of glucose through the kidney by inhibition of SGLT-2 receptors. It may seem confusing as diabetes itself causes glycosuria (loss of glucose […]